Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • AbbVie wins reversal...

    AbbVie wins reversal of 140 million dollar verdict in case over AndroGel risks

    Written by Ruby Khatun Khatun Published On 2018-07-06T09:45:41+05:30  |  Updated On 6 July 2018 9:45 AM IST
    AbbVie wins reversal of 140 million dollar verdict in case over AndroGel risks

    A U.S. judge overturned a $140.1 million verdict against AbbVie Inc in a lawsuit by a man who claimed the company misrepresented the risks of its testosterone replacement drug AndroGel, causing him to suffer a heart attack.


    U.S. District Judge Matthew Kennelly in Chicago ordered a retrial in the lawsuit brought by Tennessee resident Jeffrey Konrad, whose case is one of thousands AbbVie faces nationally over injuries blamed on AndroGel.


    In October, jurors awarded Konrad $140,000 in compensatory damages and $140 million in punitive damages after finding that AbbVie was negligent and made misrepresentations related to AndroGel that helped cause his 2010 heart attack.


    But Kennelly said the jury’s finding on the negligence claim was inconsistent with its decision to find AbbVie not liable on another claim as both involved determining if AndroGel was unreasonably dangerous and caused his heart attack.


    “When this happens, the court cannot accept one of the two inconsistent verdicts while discarding the other; both of them have to go,” Kennelly wrote.


    AbbVie did not immediately respond to a request for comment. A lawyer for Konrad also did not respond to a request for comment.


    Chicago-based AbbVie has said it faces 4,500 cases nationally in which plaintiffs claim the company did not adequately warn about risks of heart attacks, strokes and blood clots that could result from using AndroGel.


    The verdict in Konrad’s lawsuit came in one of a series of test trials in federal litigation consolidated before Kennelly over AndroGel aimed at helping both sides gauge the range of damages and define settlement options.


    Konrad had alleged that he had been using AndroGel for two months in 2010 when he suffered a heart attack. He has since recovered from his injuries.


    Thursday’s ruling marked the second time Kennelly has ordered a retrial in one of the test, or bellwether, cases.


    In December, he overturned a verdict in which jurors awarded $150 million in punitive damages but no compensatory damages to Oregon resident Jesse Mitchell, who said he suffered a heart attack after using AndroGel.


    Mitchell’s case was retried, and jurors in March ordered AbbVie to pay him $3.2 million.


    The lawsuits by Konrad and Mitchell are among four to date that have gone to trial over AndroGel. The company won the other two cases that went to trial.


    The case is In Re: Testosterone Replacement Therapy Products Liability Litigation, U.S. District Court, Northern District of Illinois, No. 14-cv-01748.





    (Reporting by Nate Raymond in Boston; editing by Jonathan Oatis and David Gregorio)




    AbbVieAndroGelblood clotsheart attacklawsuitMatthew Kennellystrokestestosterone replacement drugverdict
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok